Gata J M, García-Moreno J M, Dinca L, Sánchez-Margalet V, Navarro G, Izquierdo G
Servicio de Neurología, Hospital Universitario Virgen de la Macarena, Sevilla, España.
Rev Neurol. 1998 Dec;27(160):939-42.
We report that interferon beta decreases CD8 T cells percentage and increases CD4/CD8 cell's rate in vivo in Multiple Sclerosis (MS) patients.
We studied 40 patients (22 women and 18 men) with clinically definite active MS who received IFN beta. Twenty-six were treated with nIFN (9 MU/week) and 14 with rIFN (28 MU/week). All patients except two with secondary progressive forms presented relapsing remitting courses. Mean age and mean age at onset were 36.5 +/- 9 and 27.8 +/- 7 years respectively. Mean EDSS score was 2.96 +/- 1.8. Patients were reviewed at four weeks and every eight weeks and periodical studies of immunity were performed. T cell subpopulations (CD3, CD4, CD8 and NK) were studied byflow cytometry.
The evolution of CD8 T cell percentage showed a statistically significant decrease in all blood samples after 20 weeks of treatment with rIFN (24.3 +/- 8 vs 34.7 +/- 5 in the control group) and after 36 weeks for nIFN beta group (25.7 +/- 6 vs 33.0 +/- 4 in the control group). No changes were detected in CD4 T cell subset. The evolution of CD4/CD8 T cell rate showed an increase over the cut-off (2.200) in all blood samples after 20 weeks of treatment with rIFN (2.302 +/- 1.12, 2.332 +/- 0.99 and 2.488 +/- 1.61 for 20, 28 and 36 weeks respectively) and after 52 weeks for nIFN beta group (2.128 +/- 1.07, 2.346 +/- 1.09 and 3.168 +/- 3.87 for 52, 60 and 68 weeks respectively).
Both nIFN and rIFN beta are able in vivo to decrease CD8 percentage of T cells and increase CD4/CD8+ T cell rate. The increase in the rate is produced earlier in the rIFN treated group.
我们报告，在多发性硬化症（MS）患者体内，β干扰素可降低CD8 T细胞百分比并提高CD4/CD8细胞比率。
我们研究了40例接受β干扰素治疗的临床确诊活动性MS患者（22名女性和18名男性）。26例接受天然干扰素（nIFN，9 MU/周）治疗，14例接受重组干扰素（rIFN，28 MU/周）治疗。除2例继发进展型患者外，所有患者均呈复发缓解病程。平均年龄和平均发病年龄分别为36.5±9岁和27.8±7岁。平均扩展残疾状态量表（EDSS）评分为2.96±1.8。在4周和每8周时对患者进行复查，并进行定期免疫研究。通过流式细胞术研究T细胞亚群（CD3、CD4、CD8和NK）。
rIFN治疗20周后（对照组为34.7±5，治疗组为24.3±8）以及nIFNβ组治疗36周后（对照组为33.0±4，治疗组为25.7±6），所有血样中CD8 T细胞百分比的变化均显示出统计学上的显著下降。CD4 T细胞亚群未检测到变化。rIFN治疗20周后（20周、28周和36周时分别为2.302±1.12、2.332±0.99和2.488±1.61）以及nIFNβ组治疗52周后（52周、60周和68周时分别为2.128±1.07、2.346±1.09和3.168±3.87），所有血样中CD4/CD8 T细胞比率的变化均显示超过临界值（2.200）升高。
nIFN和rIFNβ在体内均能降低T细胞的CD8百分比并提高CD4/CD8+ T细胞比率。rIFN治疗组比率升高出现得更早。
